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Abstract
Context: This commentary discusses the implications of disease-modifying treatments for Alzheimer’s disease which
seem likely to appear in the next few years and results from a meeting of British experts in neurodegenerative diseases
in Edinburgh. The availability of such treatments would help change public and professional attitudes and accelerate
engagement with the prodromal and preclinical populations who might benefit from them. However, this would
require an updated understanding of Alzheimer’s disease, namely the important distinction between Alzheimer’s
disease and Alzheimer’s dementia.
Consensus: Since treatments are likely to be most effective in the early stages, identification of clinically relevant brain
changes (for example, amyloid burden using imaging or cerebrospinal fluid biomarkers) will be crucial. While current
biomarkers could be useful in identifying eligibility for new therapies, trial data are not available to aid decisions about
stopping or continuing treatment in clinical practice. Therefore, effective monitoring of safety and effectiveness when
these treatments are introduced into clinical practice will be necessary to inform wide-scale use. Equity of access is key
but there is a tension between universal access for everyone with a diagnosis of Alzheimer’s disease and specifying an
eligible population most likely to respond. We propose the resources necessary for an optimal care pathway as well as
the necessary education and training for primary and secondary care.
Conclusion: The majority of current services in the UK and elsewhere would not be able to accommodate the specialist
investigations required to select patients and prescribe these therapies. Therefore, a stepped approach would be necessary:
from innovating sentinel clinical-academic centres that already have capacity to deliver the necessary phase IV trials,
through early adoption in a hub and spoke model, to nationwide adoption for true equity of access. The optimism
generated by recent and anticipated developments in the understanding and treatment of Alzheimer’s disease
presents a great opportunity to innovate and adapt our services to incorporate the next exciting development in the
field of dementia.
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Driven by population ageing, dementia is now recog-
nised as one of the greatest global public health
challenges [1, 2]. The commonest aetiology of the de-
mentia syndrome is Alzheimer’s disease. Currently, only
symptomatic treatments for Alzheimer’s dementia are
available and, as yet, the findings from therapeutic trials
for drugs and biological agents to modify the course of
Alzheimer’s disease before dementia develops are univer-
sally negative [3]. However, almost 100 treatments are
currently being investigated, often targeting individuals
earlier in the disease process [4], and very promising
phase II work has been published [5]. Given ongoing
research efforts, it seems likely that interventions—be
they pharmacological or non-pharmacological multi-
modal interventions—will be available in the near future
for people diagnosed with prodromal dementia. This
would fundamentally transform how the condition is
perceived, diagnosed, and managed.
Even before the full dementia syndrome is present,
Alzheimer’s disease may manifest as changes in bio-
markers (‘preclinical’ disease) or minor cognitive symp-
toms (‘prodromal’ disease or ‘mild cognitive impairment’)
[6, 7]. These pre-dementia stages of illness rely heavily on
the understanding of an individual’s burden of disease
measured using biomarkers found in cerebrospinal fluid
(CSF) and through metabolic brain imaging. Conse-
quently, any future selection of patients for treatment will
require the ability to demonstrate such biomarker ‘abnor-
malities’ in contrast to the relatively simple clinical assess-
ments needed to initiate cholinesterase inhibitors. This
would require access to PET imaging or CSF sampling for
patient selection for treatment rather than the relatively
simple clinical assessments needed to initiate the current
symptomatic treatments for Alzheimer’s disease. This is
an exciting prospect but how such a transformation could
be implemented in the UK National Health Service (NHS)
is unclear.
Consensus meeting
To address this lack of clarity, a group of academic clini-
cians from neurology, psychiatry, and neuroradiology
disciplines and charity representatives met in Edinburgh
to discuss how the NHS and other health care providers
could respond to the future availability of a disease-
modifying treatment for Alzheimer’s disease and what
the role of biomarkers would be in the diagnostic
process. The group discussed the implications for exist-
ing clinical services and the best way to adapt services to
deliver the most appropriate and equitable access to
such therapeutic advances. The overall purpose of the
meeting and this report was to inform the predictable
evolution in services, attitudes, and understanding by
clarifying the changes to services, resource allocation,
training, and public awareness that will be necessary. If
implemented now, our message (Box 1) would also bring
tangible benefits to people currently being referred to
dementia services.
The group met once and was led through a pre-
specified agenda by the three co-chairs MNR, AB, and
CWR. The agenda covered the current use of and the
science behind imaging and other biomarkers, the
current pipeline of disease-modifying therapies for
Alzheimer’s disease, and a review of current care path-
ways in the UK. The meeting was minuted by TCR and,
before the conclusion of the meeting, the statements for
this consensus statement were discussed and unani-
mously agreed by all present. Each co-author has con-
tributed to the final drafting of this manuscript, thereby
endorsing the views and proposals herein.
Biomarkers for assessment and diagnosis
Treatments are likely to be most effective in the early
stages of Alzheimer’s disease
Alzheimer’s disease begins as early as mid-life and only
manifests as Alzheimer’s dementia once the disease is at
Box 1 Consensus message
 The advent of a disease-modifying treatment would
represent a major positive advancement in the management
of Alzheimer’s disease.
 This would change the perception of the illness to one that
is treatable, which would mark a substantial change in long-
held attitudes by the public and healthcare staff.
 Depending on the nature of the patient population for any
new medication, redesign of services for Alzheimer’s disease
is highly likely to be necessary.
 Healthcare systems will need to identify and engage with
prodromal and preclinical populations who might benefit
from such interventions. These people may not be in contact
with health services or, if they are, this will not be because of
Alzheimer’s disease.
 The implications of a disease-modifying treatment would
amount to a paradigm shift in clinical approaches to
Alzheimer’s disease, but one for which it is possible to prepare.
 Diagnosis, eligibility, and perhaps monitoring of treatment
efficacy will require diagnostics to demonstrate evidence of
cerebral amyloidosis as an example of precision medicine.
 Realistic planning is needed now to direct the evolution of
services to optimise appropriate patient access and prepare
protocols for phase IV testing of these treatments to inform
real world practice and commissioning decisions.
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an advanced stage [8, 9]. Therefore, Alzheimer’s disease
is generally far advanced by the time Alzheimer’s
dementia is diagnosed, even at an “early” stage of de-
mentia. There is an emerging consensus that optimal
disease modification would be best achieved at earlier
stages of the disease before dementia develops. Multiple
failed phase III trials (most recently solanezumab and
verubecestat [10]) seem to support this. Although stage
of disease may have mediated trial failure, other possibil-
ities include insensitive outcome measures, poor target
engagement, heterogeneity of sample across multiple
sites and languages, insufficient phase II data informing
phase III confirmation, and the possibility that the
specific targeting of the amyloid pathway is inadequate
to generate clinical benefit.
Thus, future treatments will be initially offered to
people with mid-stage Alzheimer’s disease but without
symptoms sufficiently severe to merit a diagnosis of
dementia, i.e. prodromal Alzheimer’s disease (Fig. 1).
Eventually, treatments might be offered to people at an
even earlier stage: people with biomarker evidence of
Alzheimer’s disease but minimal or no symptoms, i.e.
preclinical Alzheimer’s disease. There are several pre-
clinical trials ongoing and this is the primary focus of
the European Prevention of Alzheimer’s Dementia
(EPAD) Consortium (http://ep-ad.org/) [11].
Markers of cortical amyloidosis are fundamental
Treatment of Alzheimer’s dementia is currently ‘one size
fits all’ with anyone with the clinical syndrome being
considered for a cholinesterase inhibitor or memantine
[12]. However, since early disease-modifying treatments
for Alzheimer’s disease are likely to target amyloid
aggregation—although tau-focused therapies are also in
development—markers of cortical pathology such as
amyloidosis will become central in assessing eligibility
for new treatments. This drive towards molecular-based
therapeutics will inevitably lead to molecular-based
diagnostics. This would move the field towards precision
medicine, allowing us to offer targeted treatments to in-
dividuals with cortical amyloidosis with the prospect of
even greater precision in the future.
Therefore, markers of cortical pathology such as amyl-
oidosis will become central in diagnosing Alzheimer’s
disease—particularly at a preclinical stage—and in asses-
sing eligibility for the new treatments. All current trials
enrich the clinical sample recruited for the presence of
cortical amyloidosis and it is highly likely that these
selection criteria will be used to access the treatment in
clinical practice.
Cerebral amyloidosis can be measured directly using
amyloid PET imaging or indirectly in CSF. There is high
concordance between these diagnostic approaches [13],
so local availability, cultural factors, and staff experience
will determine the choice between the two.
The use of biomarkers for personalising intervention and
for gauging response
In a research setting, PET-Amyloid Imaging, CSF Aβ42,
tau, and p-tau are useful biomarkers to differentiate
people with Alzheimer’s dementia from controls [14].
However, the current utility of these biomarkers in a
clinical context, given the low specificity of these tests
(e.g. CSF Aβ) for Alzheimer’s dementia in the elderly
and the inconsistent quality of the evidence base is less
clear [15, 16]. Eligibility criteria for new disease-
modifying treatments would initially need to echo the
entry criteria for the phase III trials for the treatment, all
of which now include a marker of amyloid burden. Fur-
ther enrichment of the clinical population using APOE
status should only be recommended in clinical practice
where there was a demonstrable pharmacogenetic effect
noted in the treatment’s licensing trial (either for efficacy
or safety) unless new evidence emerges for its utility in
risk prediction models.
Early disease-modifying treatments will probably slow,
rather than reverse, neurodegeneration and so on-going
treatment may be required to maintain this effect. Treat-
ment might be lifelong and last several decades. How-
ever, there are currently no reliable and validated
patient-related outcome instruments for the early stages
of the disease. To ensure ongoing clinical and cost-
effectiveness, explicit and early stopping criteria would
be important, which will require a surrogate biomarker
response (Fig. 2). However, no biomarker currently
studied is known to be suitable for this purpose and
current trials (except DIAN-TU [17]) use intermediary
biomarker phenotypes such as PET-Amyloid to deter-
mine if a treatment is futile. Furthermore, since clinical
trials assess this at a group level and not for individuals,
one would only be able to derive a probability of a lack
of long-term success for an individual in clinical
practice. Therefore, there is currently no reliable way to
Fig. 1 The continuum of Alzheimer’s disease pathology from the
preclinical and prodromal stages to overt clinical dementia plus the
relative importance of biomarker assessment and functional assessment
at the different stages
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decide whether an individual should stop or continue
other than on the grounds of safety. Embedding this out-
come into phase II and III trials would facilitate greater
appropriate access to therapies by minimizing inappro-
priate, ineffective use, but the limited duration of these
trials (up to two years) would be a challenge.
Accessing the vast amount of observational data being
gathered through programmes like the European
Medical Information Framework (EMIF) and Dementias
Platform UK (DPUK) will give an indication of the ex-
pected rate of changes in sub-populations—though direct
comparison of these data with randomised, controlled trial
data would be problematic from a statistical perspective.
Phase IV testing—as advocated below—would address
some of these issues as would the use of readiness cohorts
(e.g. EPAD) that can use run-in data from the same popu-
lation as the trial to help guide expected placebo declines
in the trial population.
The importance of phase IV testing
Substantial post-marketing research must be carried out
before disease-modifying therapies are widely used and
this should be co-produced by the public sector, char-
ities, and industry alongside agreements on pricing and
reimbursement that reflect optimum value for the NHS
and patients. This would encompass accumulation of
safety data as well as real world experience on mid- to
long-term patient outcomes (including patient-related
outcome measures), compliance, service impact, health
economics, and longitudinal biomarker analysis to assist
the establishment of a response biomarker. Generic
phase IV protocols must be developed before these
drugs are marketed so they can be safely and effectively
introduced as widely as possible. This will involve close
co-operation with bodies such as the National Institute
for Health and Care Excellence (NICE), which approves
the use of new treatments in the English and Welsh
National Health Service and has major influence else-
where. The establishment of better systems for gathering
information from clinical practice would ease this phase
IV testing if routinely collected electronic data contained
phenotypic, clinical, and resource utilisation variables
relevant to brain health in order to undertake large scale,
standing phase IV work.
Policy and professional development
Equity of access is key
New treatments will initially be provided to patients in
whom their use will be clinically and cost-effective and it
is vital that when a new treatment becomes available it
can be offered to everyone who is eligible. However,
there is an inherent tension between specifying the eli-
gible population through biomarkers (not to mention
the uneven spread of tertiary-level expertise in dementia
diagnosis and treatment) and equity of access—for ex-
ample, for people of all ages, from all ethnic groups and
from all localities. Patient and public engagement will be
important to ensure that treatment provision is not
perceived as inequitable.
In the first instance, prescription of disease-modifying
treatments may only be possible in centres with capacity
to undertake the partner diagnostic work as well as
Fig. 2 Hypothetical model of intervention with a disease-modifying treatment for Alzheimer’s disease. The curved line depicts a biomarker reflecting a
specific drug target which responds to treatment. a depicts the courses of mechanism-specific drug(s). b depicts the accompanying tailored risk factor
intervention and advice. The dotted grey line indicates the disease course without treatment—progressive functional deterioration. The solid grey line
indicates the disease course with treatment—slower deterioration and better functional outcome, i.e. the delay of onset of clinical dementia. Adapted
from Hampel et al. [12]
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monitoring for safety issues and undertaking the phase
IV work described above. Nevertheless, within these
centres (which should act as regional hubs for prescrib-
ing) equity of access should be mandated and
monitored, and access extended as quickly as possible.
Close regional collaboration across NHS trust boundar-
ies will be essential to this.
Professionals will need specific training
There will need to be substantial education and training
provided for primary and secondary care professionals
about new disease-modifying treatment for Alzheimer’s
disease. In primary care this would need to focus on
early symptoms and risk factors to ensure timely referral
whereas in secondary care it would cover the safe and
effective use of biomarkers. Indeed, surveying current
provision of dementia services and knowledge and atti-
tudes should be done immediately to assess current
service capacity and identify training needs. This could
build on the existing Memory Services National
Accreditation Programme (MSNAP) in England and Wales.
The UK has an established pool of clinical academics
who already use these interventions in clinical trials as
well as PET imaging and CSF biomarkers, either
routinely or on selected patients in their clinical practice
or research. However, further planning will be important
and necessary to ensure this knowledge and expertise
can be shared with all relevant staff groups across the
NHS who will be operating from a diversity of clinical
settings and backgrounds.
This is an opportunity to reconfigure our services
Even without formal assessment of national and regional
capacity, it is clear that increased access to neuroimaging
and CSF analysis would be needed to support the add-
itional diagnostic processes required for the appropriate
targeting of new treatments. An agreed optimal care
pathway would minimize idiosyncratic and inefficient
practice. Initially rolled out in centres with relevant re-
sources and expertise (forming a Brain Health Clinic
Network), the resulting real world experience could be
used to develop pathways for broader adoption through-
out the NHS.
Dementia services are currently run under a predom-
inantly psychiatric model of care with a symptomatic
and palliative focus. However, a reconfigured service
would require seamless collaboration between disci-
plines, patient groups, and specialties in order to expand
the dementia-focussed clinical services to include an
Alzheimer’s disease and pre-dementia service for cogni-
tively healthier, younger patients. Indeed, engagement
with other specialties who may be in contact with such
patients because of other health conditions will be an
important necessary development. The focus would be
on maintaining brain health using risk reduction,
resilience building, molecular-based diagnostics, and
delivering complex pharmaceutical interventions.
The optimal care pathway
Who should be referred?
Many people—including those already diagnosed and
not yet diagnosed with Alzheimer’s disease—would
probably present to their GP when the marketing of a
disease-modifying treatment was covered in the media.
This has substantial resource implications for an already
busy workforce. The number of specialists with relevant
experience and appropriate facilities for diagnosis and
treatment will represent important limitations.
Memory services currently see patients with later pro-
dromal disease and early dementia but, over time, the
profile of patients would also include preclinical and
early prodromal populations. The future role of the GP
as gatekeeper in general is uncertain [18] but direct
access to a diagnostic and therapeutic service for
Alzheimer’s disease may not be feasible or desirable.
With treatment likely to involve complex eligibility as-
sessment, including biomarkers, one could advocate GPs
referring everyone with suspected Alzheimer’s disease to
a specialist service. However, only a relatively small pro-
portion of these people referred would meet the eligibil-
ity criteria for a new treatment. On the other hand,
while many people currently present with moderate or
severe dementia, in the future, hopefully the majority of
people will be diagnosed much earlier, even in the pro-
dromal/preclinical stages. Better cognitive tests for use
in primary care with improved specificity and sensitivity
for Alzheimer’s disease to help with referral decisions
are currently in development. This would support
primary care triage of patients into secondary care.
However, until such tests exist, selection for treatment
with disease-modifying therapies could only take place
in specialist centres.
What would an optimal specialist service require?
Disease-modifying therapies will be specific to Alzheimer’s
disease and so there will be an even greater need to sub-
type neurodegenerative diseases accurately. For this diag-
nostic process, access to a variety of imaging modalities to
differentiate Alzheimer’s disease from other neurodegen-
erative conditions would be necessary—structural imaging
(MRI, CT), FDG-PET, DAT, as well as amyloid and pos-
sibly tau PET (plus access to radiolabelled tracers)—plus
neuroradiological and nuclear medicine expertise for the
interpretation of these imaging modalities and their
contextualisation alongside other assessments. Facilities
for lumbar puncture would also be needed to ascertain
cortical amyloidosis if PET imaging is not possible or
acceptable to the patient.
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The multidisciplinary team should include a specialist
doctor; the skills of neurology, psychiatry, and geriatric
medicine will all be relevant and should be represented.
Furthermore, a new specialist nurse role could emerge,
analogous to Macmillan nurses but with distinct skills
from those already in existence. If pharmacogenetic test-
ing (e.g. APOE ε4 status) is required for dose or subject
selection, then embedding a genetic counselling service
will also be required. Obviously, an appropriate setting
to impart any diagnosis in a sensitive manner and to
provide ongoing post-diagnostic information and
support is vital. This service should be able to follow
up people who have been commenced on a disease-
modifying agent and should be able to escalate care
in the case of adverse reactions during treatment
administration. This might mean location in or near a
general hospital.
A distinct approach for the preclinical, prodromal, and
dementia stages of Alzheimer’s disease would be neces-
sary. A comprehensive service could provide all these
elements, but different expertise, skills, and care path-
ways are needed at different stages of disease. However,
whether a broad, “one stop shop” is feasible or whether
a tiered approach with primary, secondary (diagnostic),
and tertiary (therapeutic) levels would be necessary is
uncertain. In any case, transition through the service
must be seamless. Furthermore, people with dementia
often report that they wish services to be close to home.
That any new clinical service will have to keep pace
with updates in diagnostic criteria for Alzheimer’s
disease and other neurodegenerative conditions, it is
noted that new criteria being proposed increasingly rely
on biomarker evaluation which re-emphasises the need
for clinical services to have access to and experience
with biomarker testing as part of their clinical work-up.
How many people might be eligible for a new treatment?
Based on current service capacity, gradual implementa-
tion, and variable take up of the new service, the likely
number of eligible patients will initially be hundreds
rising to tens of thousands of people within a few years
as services adapt and increased public awareness helps
case ascertainment in primary care. However, data to
back up this estimate and further detailed modelling are
needed to inform planning and resource allocation.
Communication
Disease-modifying treatments would change the way we
all think about neurodegenerative diseases and dementia
There is much confusion in many people’s minds
(including the public, clinicians, and policy makers)
about dementia—for example, whether it is the same as
Alzheimer’s disease. Irrespective of this, most people
currently think of dementia as an untreatable,
progressive condition affecting older people. The advent
of a disease-modifying treatment would change this per-
ception. The view that Alzheimer’s disease can only be
diagnosed in the dementia stage of the illness must be
challenged as the prognostic accuracy of pre-dementia
disease models improves. This is familiar territory in
other branches of medicine where treatments are
commonly started before there are clinical signs or
symptoms. A major societal benefit of the advent of
disease-modifying drugs would be the end of the percep-
tion of Alzheimer’s disease as an incurable, inevitably
fatal disease of older people and its replacement with a
more optimistic position with a high likelihood of modi-
fication of the disease course.
The Edinburgh Consensus group recognised the need to
advocate for the changes outlined above as well as con-
tinually reviewing progress in the UK and elsewhere as
science advances, care models adapt, and therapies be-
come available. These are truly innovative and optimistic
times in the understanding and treatment of earlier
Alzheimer’s disease. Modifying the disease course with
multimodal interventions and personalised treatment
plans—including risk reduction—will soon be possible.
Working closely with European and global colleagues in
the academic, clinical, charitable, and commercial sectors
and with patient groups will help the largest number
of people access the right therapies to prevent or
significantly delay the onset of Alzheimer’s dementia.
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